Literature DB >> 8425138

The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia.

T E Goldberg1, R D Greenberg, S J Griffin, J M Gold, J E Kleinman, D Pickar, S C Schulz, D R Weinberger.   

Abstract

Psychiatric symptoms and cognition were assessed in 13 patients with schizophrenia, one patient with schizoaffective disorder, and one patient with psychosis not otherwise specified while they received a conventional neuroleptic and again after an average of 15 months on clozapine. Despite improvements in psychiatric symptoms, attention, memory, and higher-level problem-solving were essentially unchanged. This suggests that certain cognitive deficits are relatively independent of psychotic symptoms in schizophrenia, and are probably central and enduring features of the disorder. Cognitive disability appeared to have been rate-limiting in the sample's rehabilitation, as patients' social and vocational adjustment remained marginal during the study. We also observed that treatment with clozapine was associated with a decline in some memory functions; the potent anticholinergic properties of the drug may have been responsible for this.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8425138     DOI: 10.1192/bjp.162.1.43

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  40 in total

Review 1.  Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.

Authors:  S E Purdon
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.

Authors:  Blanka Kores Plesnicar; Bojan Zalar; Martina Tomori; Ivan Krajnc
Journal:  Wien Klin Wochenschr       Date:  2003-01-31       Impact factor: 1.704

3.  Cognitive effects of olanzapine treatment in schizophrenia.

Authors:  Susan R McGurk; M A Lee; K Jayathilake; Herbert Y Meltzer
Journal:  MedGenMed       Date:  2004-05-10

Review 4.  Neuroimaging of cognitive disability in schizophrenia: search for a pathophysiological mechanism.

Authors:  J D Ragland; J Yoon; M J Minzenberg; C S Carter
Journal:  Int Rev Psychiatry       Date:  2007-08

Review 5.  Predictors and markers of clozapine response.

Authors:  Carmen Chung; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

6.  Prefrontal serotonin depletion affects reversal learning but not attentional set shifting.

Authors:  H F Clarke; S C Walker; H S Crofts; J W Dalley; T W Robbins; A C Roberts
Journal:  J Neurosci       Date:  2005-01-12       Impact factor: 6.167

Review 7.  Psychomotor slowing in schizophrenia.

Authors:  Manuel Morrens; Wouter Hulstijn; Bernard Sabbe
Journal:  Schizophr Bull       Date:  2006-11-08       Impact factor: 9.306

8.  Propranolol blocks chronic risperidone treatment-induced enhancement of spatial working memory performance of rats in a delayed matching-to-place water maze task.

Authors:  Ee Peng Lim; Vivek Verma; Rajini Nagarajah; Gavin S Dawe
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

9.  Nonsocial and social cognition in schizophrenia: current evidence and future directions.

Authors:  Michael F Green; William P Horan; Junghee Lee
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

10.  HDAC2 as a new target to improve schizophrenia treatment.

Authors:  Mitsumasa Kurita; Terrell Holloway; Javier González-Maeso
Journal:  Expert Rev Neurother       Date:  2013-01       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.